Protagonist Therapeutics (PTGX) Work In Process (2021 - 2024)

Protagonist Therapeutics has disclosed Work In Process across 4 years of filings, most recently posting $165.0 million for Q4 2024.

• Work In Process for Q4 2024 came in at $165.0 million, up 1550.0% year-over-year; the trailing twelve-month figure through Dec 2024 was $165.0 million (up 1550.0% YoY), and the FY2024 annual result was $165.0 million, up 1550.0% from the prior year.
• Work In Process came in at $165.0 million for Q4 2024 at Protagonist Therapeutics, up from $43000.0 in the prior quarter.
• In the past five years, Work In Process ranged from a high of $300.0 million in Q1 2024 to a low of $10000.0 in Q4 2022.
• The 4-year median for Work In Process is $1.6 million (2021), against an average of $68.1 million.
• Across the five-year window, Work In Process slumped 99.36% in 2022 and soared 99900.0% in 2023, its largest moves.
• Protagonist Therapeutics' Work In Process stood at $1.6 million in 2021, then plunged by 99.36% to $10000.0 in 2022, then jumped by 99900.0% to $10.0 million in 2023, then soared by 1550.0% to $165.0 million in 2024.
• The last three Work In Process figures came in at $165.0 million (Q4 2024), $43000.0 (Q2 2024), and $300.0 million (Q1 2024), per Business Quant data.